Morgan Stanley analyst Thibault Boutherin raised the firm’s price target on Novartis (NVS) to CHF 105 from CHF 100 and keeps an Equal Weight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis AG: Balancing Promising Pipeline Developments with Valuation and Risk Concerns
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
- Novartis Stock (NVS) Beats Harder on $5.2B Chinese Heart Disease Deal
- Oppenheimer says Olema collaboration with Pfizer could lead to bidding war
- Arrowhead (ARWR) Stock Soars over $200M Deal with Swiss Pharma Giant Novartis